NCCRP1 Inhibitors
Inhibitors of NCCRP1 are diverse in their mechanisms of action, each affecting different pathways that are plausibly connected to the functional activity of NCCRP1. PI3K inhibitors, such as Wortmannin and LY294002, target upstream regulators of mTOR signaling, a key player in cell proliferation and survival. Inhibition of this pathway is likely to result in a decrease in NCCRP1 activity if it is involved in any aspect of mTOR-related processes. Rapamycin adds to this category by directly targeting mTORC1, further propagating the potential for decreased NCCRP1 activity due to its role in cellular growth control.
MEK inhibitors, such as PD98059 and U0126, and the p38 MAPK inhibitor SB203580, disrupt the MAPK pathway, which is crucial for cell proliferation, differentiation, and response to stress. Suppression of this pathway could lead to an indirect decrease in NCCRP1 activity, especially if NCCRP1 is involved in signaling cascades that rely on MAPK/ERK or p38 MAPK for their execution. The JNK inhibitor SP600125 can also indirectly affect NCCRP1 by inhibiting stress-activated protein kinase/c-Jun N-terminal kinase pathways, which are important in cellular responses to stress, inflammation, and apoptosis. If NCCRP1 is directly or indirectly involved in these stress response pathways, then inhibition of JNK signaling could reduce NCCRP1 activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor that prevents phosphorylation of AKT, leading to reduced mTOR activation. NCCRP1, being associated with cellular proliferation pathways, would have its activity indirectly inhibited due to suppression of mTOR signaling, which is essential for cell growth and metabolism that NCCRP1 may be a part of. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor that impedes the mTORC1 complex, leading to decreased protein synthesis and cell proliferation. Since NCCRP1 functions may be intertwined with these cellular processes, inhibition of mTOR would result in indirect inhibition of NCCRP1 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A specific inhibitor of PI3K, leading to blocked AKT phosphorylation and subsequent downstream signaling reduction, including mTOR pathways. This blockade can indirectly inhibit NCCRP1 if its function is related to these signaling pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
MEK inhibitor that interrupts the MAPK/ERK pathway, which is involved in cell proliferation and survival. If NCCRP1 is part of or dependent on this signaling cascade, inhibition by PD98059 would result in decreased NCCRP1 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 MAPK inhibitor that can impede cellular responses to stress and cytokines. If NCCRP1 activity is modulated by or dependent on the p38 MAPK pathway, then inhibition of this pathway would indirectly diminish NCCRP1 function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor that blocks the JNK signaling involved in stress responses, inflammation, and apoptosis. If NCCRP1 is part of these cellular processes, SP600125 can indirectly inhibit NCCRP1 by halting JNK pathway signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
Inhibitor of MEK1/2, leading to blockade of the MAPK/ERK signaling pathway. If NCCRP1 function is associated with this pathway, then U0126-induced suppression would indirectly inhibit NCCRP1 activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
Src family kinase inhibitor that disrupts signaling pathways involved in cell growth and differentiation. If NCCRP1 is functionally connected to these pathways, PP2-mediated inhibition could lead to a decrease in NCCRP1 activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor that can lead to the accumulation of misfolded proteins and induce cell stress responses. If the function of NCCRP1 is associated with protein turnover or stress responses, inhibition of the proteasome by Bortezomib could indirectly reduce NCCRP1 activity. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
SERCA pump inhibitor that disrupts calcium homeostasis, leading to ER stress and the unfolded protein response. If NCCRP1 activity is linked to calcium signaling or ER function, Thapsigargin could result in indirect inhibition of NCCRP1. | ||||||